Pulmonx (STU:4NI) Ending Cash Position : €67.96 Mil (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Pulmonx Ending Cash Position?

Pulmonx's Ending Cash Position for the quarter that ended in Dec. 2024 was €67.96 Mil.

Pulmonx's quarterly Ending Cash Position declined from Jun. 2024 (€59.20 Mil) to Sep. 2024 (€57.28 Mil) but then increased from Sep. 2024 (€57.28 Mil) to Dec. 2024 (€67.96 Mil).

Pulmonx's annual Ending Cash Position declined from Dec. 2022 (€96.26 Mil) to Dec. 2023 (€76.83 Mil) and declined from Dec. 2023 (€76.83 Mil) to Dec. 2024 (€67.96 Mil).

Pulmonx Ending Cash Position Historical Data

The historical data trend for Pulmonx's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pulmonx Ending Cash Position Chart

Pulmonx Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Ending Cash Position

Get a 7-Day Free Trial

190.53

131.61

96.26

76.83

67.96

Pulmonx Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Ending Cash Position	Get a 7-Day Free Trial															76.83	64.76	59.20	57.28	67.96

Pulmonx Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Pulmonx's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	80.013	+	-12.053
	=	67.96

Pulmonx's Ending Cash Position for the quarter that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	60.71	+	7.25
	=	67.96

Pulmonx Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Pulmonx's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Pulmonx Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pulmonx Corp (STU:4NI) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

LUNG:USA 4NI:Germany

Address

700 Chesapeake Drive, Redwood, CA, USA, 94063

Website

https://www.pulmonx.com

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Pulmonx Headlines

No Headlines